Works on human cells, first time in world says Takis CEO
Rome, May 4 – An Italian coronavirus vaccine developed by the Takis company has antibodies generated in mice that work on human cells, according to tests carried out at Rome’s infectious-disease Spallanzani Hospital, Takis CEO Luigi Aurisicchio told ANSA Monday.
He said that for the first time in the world a COVID-19 candidate vaccine has neutralized the virus in human cells.
This is the most advanced stage of testing of a candidate vaccine created in Italy, he said.
He said hat human tests are expected after this summer.